



KASR ALAINY

Study of Plasma Long Pentraxin 3 (PTX3) as a Marker of Endothelial Dysfunction in Type 2 Diabetes Mellitus

THESIS

*Submitted for the partial Fulfillment of M.D. Degree
In
Internal Medicine*

**By
Elham Mohamed Yousief**

MSc. (Cairo University)

Supervisors

**Prof. Dr. Amr Abdel Hady
Al-Meligi**

*Professor of Internal Medicine
Faculty of Medicine
Cairo University*

**Prof. Dr. Alaa Mahmoud Abdel
Hamid**

*Professor of Internal Medicine
Faculty of Medicine
Cairo University*

Dr. Manal Adly Aziz

*Assistant Professor of Internal Medicine
Faculty of Medicine
Cairo University*

Dr. Marian Fathy Ishak

*Assistant Professor of Chemical Pathology
Faculty of Medicine
Cairo University*

**Faculty of Medicine
Cairo University
2012**

Acknowledgement

*I wish to express my deep gratitude to **Prof. Dr., Amr Abdel Hady Ibrahim Al Meligi** Prof. of internal medicine, Faculty of Medicine, Cairo University for his constant guidance, constructive supervision and following the performance and progress of this thesis. I much benefited from his creative thinking, valuable suggestions and constructive criticism.*

*I am greatly indebted to **Prof. Dr., Alaa Mahmoud Abdel Hamid** Prof. of internal medicine, Faculty of Medicine, Cairo University for his constant guidance and valuable assistance in reading, revision and discussion of all results of this thesis.*

*I am greatly expressing my gratitude towards **Dr. Manal Adly Aziz** Assistant Prof. of internal medicine, Faculty of Medicine, Cairo University for her constant guidance and valuable assistance in reading.*

*I would also like to express my gratitude and appreciation toward **Dr. Marian Fathy Ishak**, Assistant professor of chemical pathology Unit .Faculty of Medicine, Cairo University for her effective work and sharing in interpretation and analysis of the results of our thesis.*

Finally, I appreciate the cooperation of our dear patients; I hope this work offers a chance for a better state of health which they deserve after their long pains and suffering.

Elham Mohamed Yousief

Abstract

Albuminuria and inflammation predict cardiovascular events. Pentraxin 3, an inflammatory mediator produced by endothelial cells, may have a role in atherogenesis.

Our study was conducted on 50 patients with type 2 diabetes mellitus classified into two groups: group I which included 25 type 2 diabetes patients with normal UAE and group II included 25 patients with type 2 diabetes with microalbuminuria and 20 healthy volunteers as a control group. We aimed to measure plasma levels of long pentraxin 3 (PTX3) in patients with type 2 DM with and without microalbuminuria with normal renal function and without overt cardiovascular disease and to evaluate its utility in the early detection of endothelial dysfunction compared to other known markers of endothelial dysfunction (vWF activity and flow dependent arterial dilatation).

We found that type 2 diabetic patients with microalbuminuria and normal GFR (stage 1 CKD) have significantly higher PTX-3 concentrations and significantly lower flow mediated dilatation (FMD) than normal individuals and diabetics with normal UAE and normal kidney functions also vWF activity are significantly higher in patients with type 2 diabetes with normal UAER (group I) and in patients with microalbuminuria (group II) compared to controls. There was a significant positive correlation between PTX3 and vWF activity, duration of diabetes, fasting glucose, HbA1c, cholesterol and triglyceride and a significant negative correlation between PTX3 and FMD in all diabetic patients.

Conclusion: Our study suggests a link among albuminuria, markers of ED, and development of atherosclerotic complications through pathways that may involve PTX3.

Key words: (Endothelial dysfunction, type 2 diabetes, long pentraxin 3)

List of Content

	Pages
List Abbreviation	I
List of Tables	VII
List of Figures	VIII
Introduction & Aim of Study	1
Review of Literature	
Chapter (1)	
Endothelium	3
Chapter (2)	
Assessment of endothelial function.....	32
Chapter (3)	
Long pentaxin 3.....	43
Chapter (4)	
Type 2 diabetes and diabetes complications.....	53
Materials and Methods	84
Results	93
Discussion	117
Summary	128
References	130
Arabic Summary	174

List of Abbreviations

AACE	American association of clinical endocrinologist
ABI	Ankle brachial index
ACCF	American College of Cardiology Foundation
ACCORD	Action to Control Cardiovascular Risk in Diabetes)
ACE	Angiotensin converting enzyme
ACSs	Acute coronary syndromes
ADA	American diabetes association
ADMA	Asymmetric dimethylarginine
ADVANCE	Action in Diabetes and Vascular Disease
ADP	Adenosine di-phosphate
AECAs	Anti-endothelial cell antibodies
AGEs	Advanced glycation end products
AMP	Adenosine mono-phosphate
AP-1	Activator protein-1
AR	Aldose reductase
ARBs	Angiotensin receptor blockers
APS	Antiphospholipid syndrome
ARBs	Angiotensin receptor blockers
ATT	Anti-thrombotic Trialists'
BH4	Tetrahydrobiopterin
BCG	Bacille Calmette-Guerin
BMI	Body mass index
CAD	Coronary artery disease
CHD	Chronic heart disease
c-GMP	cyclic Guanosine monophosphate
cIMT	Carotid intima media thickness

CKD	chronic kidney disease
CNS	Central nervous system
CRP	C-reactive protein
CSF	Colony stimulating factor
CV	Cardiovascular
CVD	Cardiovascular disease
DAG	Diacylglycerol
DCs	Dendritic cells
DCCT	Diabetes Control and Complications
DM	Diabetes mellitus
DPN	Diabetic peripheral neuropathy
DRS	Diabetic Retinopathy Study
dsDNA	Double stranded DNA
eCcr	Estimated creatinine clearance
EDHF	Endothelium-derived hyperpolarizing factor
ED-FMD	Endothelial dependent flow-mediated vascular dilation
ED	Endothelial dysfunction
ELISA	Enzyme linked immune sorbent assay
eNOS	Endothelial NOS
EPCR	Endothelial protein C receptor
EPCs	Endothelial progenitor cells
ETDRS	Early Treatment Diabetic Retinopathy Study
ESRD	End-stage renal disease
ET	Endothelin
FBS	Fasting blood sugar
FDA	Food and Drug Administration
FFA	FFA
FMD	Flow mediated dilatation

GAP	Glyceraldehydes-3-phosphate
GFR	Glomerular filtration rate
GLUT	Glucose transporters
GTN	Nitroglycerin
GTP	Guanosine triphosphate
H2O2	Hydrogen peroxide
HDL	High density lipoprotein
HDLC	High density lipoprotein cholestrol
HbA1c	Glycosylated haemoglobin
HRP	Horse radish peroxidase
HUVEC	Human umbilical vein endothelial cells
ICAM-1	Intercellular adhesion molecule-1
ICH	Intracranial hemorrhage
IGM	Impaired glucose metabolism
IGT	Impaired glucose tolerance
IL	Interleukin
IMT	Intima media thickness
iNOS	Inducible or inflammatory NOS
INVEST	International Verapamil SR-Trandolapril
IKB	Inhibitor of kappa B
IR	Insulin resistance
IRD	Inflammatory rheumatic disease
IS	Insulin-sensitive
LDL	Low density lipoprotein
LADA	Latent autoimmune diabetes in adults
LFA-1	Leucocyte function associated antigen-1
LOPS	Loss of proprioceptive sensations
LP	Lipid peroxidation

LPS	Lipopolysaccharide
MAP	Mitogen activated protein
MBF	Myocardial blood flow
MCP-1	Monocyte chemotactic protein-1
MI	Myocardial infarction
MCTD	Mixed connective tissue disease
MDRD	Modification of Diet in Renal Disease
MoDC	Monocytes DC
MODY	Maturity-onset diabetes of the young
MPO	Myeloperoxidase
MyDC	Myeloid DC
NADPH	Nicotinamide adenine dinucleotide
NCEP	National Cholesterol Education Panel
NFkB	Nuclear factor kappa B
NGT	Normal glucose tolerance
NHANES	National Health and Nutrition Examination Surveys
NK	Natural killer Cells
NO	Nitric oxide
NOS	Nitric oxide synthase
nNOS	Neuronal NOS
nRNP	Ribonucleoproteins
O.D.	Optical density
OGTT	Oral glucose tolerance test
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAH	Pulmonary arterial hypertension
PAI-1	Plasminogen activator inhibitor-1
PARP	Activation of poly (ADP-ribose) polymerase

PBMCs	Peripheral bone marrow cells
pDC	Plasmoid DC
PIP3	Phosphatidylinositol triphosphate 3
PKC	Protein kinase C
PTX3	Long pentraxin 3
RA	Rheumatoid arthritis
RAS	Renin-angiotensin system
ROS	Reactive oxygen species
SAP	Serum amyloid P component
SDH	Sorbitol dehydrogenase
sICAM-1	Soluble intercellular adhesion molecule-1
SLE	Systemic lupus erythomatouses
SSc	Systemic sclerosis
SPECT	Single photon emission computed tomography
STIMS	The Swedish Ticlopidine MulticenterStudy
sTNFR-I	Soluble TNF receptor I
sVCAM-1	Soluble vascular cell adhesion molecule-1
TCAs	Tricyclic antidepressants
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TMB	Tetra methyl benzidine
TFPI	Tissue factor pathway inhibitor
TIA	Transient ischemic attack
TLR	Toll-like receptors
TM	Thrombomodulin
TNFα	Tumour necrosis factor α
TSG	TNF-stimulated genes
tPA	Tissue plasminogen activator

UAE	Urinary albumin excretion
U1 RNP	U ₁ ribonucleoprotein
UKPDS	UK prospective diabetes study
VCAM	Vascular cell adhesion molecule
VEGF	Vascular endothelial growth factor
VLA-4	Very late antigen-4
vWF	von Willebrand factor
vWFAg	Von Willebrand factor antigen
WHO	World of health and organization

List of Tables

Tables		Pages
1	Mean age and sex distribution among the study groups.	96
2	Duration of diabetes between the diabetic groups.	96
3	Comparative study of BP, BMI and waist circumference among the study groups.	97
4	Comparison of fundus and sensory Peripheral nerve examination between both diabetic groups.	97
5	Comparison of biochemical data among the study groups.	98
6	FMD of brachial artery between the study groups.	99
7	Comparison of von-willebrand factor activity between the study groups.	99
8	Comparative study of long pentraxin3 between the study groups.	99
9	Correlation of long pentraxin3 to all data in diabetic patients with no microalbuminuria.	100
10	Correlation of long pentraxin3 to all data in diabetic patients with microalbuminuria.	101
11	Correlation of long pentraxin3 to all data in our study groups.	102

List of Figures

Figures		Pages
1	Metabolic and synthetic functions of endothelial cells.	4
2	Transcellular transport in endothelial cells by Caveolae.	7
3	Central role of endothelial function in the causation and progression of atherosclerosis.	17
4	Molecular features of long pentraxin 3.	44
5	Protein kinase C and polyol pathways in the pathogenesis of diabetic complications.	60
6	Standard curve for long pentraxin 3 assay	91
7	Experimental setup for assessing flow-mediated dilation of the brachial artery.	92
8	Age of the study groups.	103
9	Sex distribution among the study groups.	103
10	Duration of treatment among the study groups.	104
11	Blood pressure evaluation between the study groups.	104
12	Waist circumference among the study groups.	105
13	BMI evaluation among the study groups.	105
14	Sensory peripheral neuropathy among the study groups .	106
15	Fundus evaluation among the study groups.	106
16	FBS among the study groups	107
17	HbA1c among the study groups	107
18	Serum creatinine among the study groups	108
19	Creatinine clearance among the study groups	108
20	Urinary albumin excretion rate among the study groups	109
21	Lipid profile among the study groups	109
22	Mean FMD of brachial artery among the study groups	110
23	Von-willebrand factor activity in our study groups	110

24	Long pentraxin3 in the study groups	111
25	Positive correlation between long pentraxin 3 and duration of diabetes in both diabetic groups	111
26	Positive correlation of long pentraxin2 with duration of diabetes in diabetic patient with no microalbuminuria.	112
27	Positive correlation between long pentraxin3 and FBS in all studied groups.	112
28	Significant positive correlation between pentraxin3 and HbA1C in all studied groups.	113
29	Negative correlation between long pentraxin3 and creatinine clearance in all studied groups.	113
30	Positive correlation between long pentraxin3 and cholesterol levels in all studied groups.	114
31	Positive correlation between long pentraxin3 and triglycerides level in all studied groups.	114
32	Negative correlation between long pentraxin3 and FMD in all studied groups.	115
33	Positive correlation between pentraxin3 and vWF factor activity in all studied groups.	115
34	Positive correlation between long pentraxin 3 and vWF factor activity in diabetic patients with microalbuminuria	116



Introduction

One of the earliest clinically detectable abnormalities in diabetic nephropathy is microalbuminuria that eventually progresses to albuminuria and overt nephropathy. Albuminuria is viewed as a marker of glomerular disease and is nowadays recognized as a strong and independent predictor of cardiovascular disease (CVD) risk among individuals with and without diabetes, independent of other recognized risk determinants, including reduced glomerular filtration rate (GFR) (*Stehouwer and Smulders, 2006*). Although the nature of the link between urinary albumin excretion (UAE) and cardiovascular risk still remains poorly understood, common pathophysiologic processes may contribute, such as endothelial dysfunction (ED) and/or chronic low grade inflammation (*Stehouwer and Smulders., 2006*). In fact, increased UAE is considered to indicate ED (*Stehouwer et al., 2004*). At the same time, UAE has been associated with plasma inflammatory mediators (*Abrahamian et al., 2007*).

Long pentraxin 3 (PTX3) is a multimeric inflammatory mediator that is structurally linked to short pentraxins, such as C-reactive protein (CRP) and serum amyloid P component (*Mantovani et al., 2008*). PTX3 is produced by a variety of tissues and cells, including vascular endothelial cells and macrophages (*Mantovani et al., 2006*). Because of its extrahepatic synthesis (in contrast to CRP), the PTX3 level is believed to be a true independent indicator of disease activity because PTX3 is produced at sites of inflammation and is intimately linked to ED (*Fazzini et al., 2001*). PTX3 levels are elevated in patients with chronic kidney disease (CKD) (*Boehme et al., 2007*) and represent a novel mortality risk



factor in stage 5 CKD, independent of traditional risk factors and CRP itself (*Tong et al., 2007*). A strong associations was observed between PTX3 and markers of ED, such as soluble vascular cellular adhesion molecule-1 (VCAM-1) and fibrinogen, in patients with chronic kidney disease had (*Tong et al., 2007*) led to hypothesis that PTX3 may link albuminuria with ED and, ultimately, atherothrombotic complications.

Background:

Albuminuria and inflammation predict cardiovascular events. Pentraxin 3, an inflammatory mediator produced by endothelial cells, may have a role in atherogenesis.

Aim of the Study

The aim of this study is to measure plasma levels of long pentraxin 3 in patients with type 2 DM with and without microalbuminuria (without clinical cardiovascular disease) and to find its relationship to other known markers of endothelial dysfunction (vWF activity and flow dependent arterial dilatation), degree of glycemic control.